Trial Profile
A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca; AstraZeneca AB
- 15 Mar 2023 Status changed from active, no longer recruiting to completed.
- 27 Jan 2023 Planned End Date changed from 27 Dec 2022 to 29 Dec 2023.
- 23 Feb 2022 Planned End Date changed from 2 Nov 2021 to 27 Dec 2022.